Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, requires iron for survival. In Mtb, MhuD is the cytosolic protein that degrades imported heme. MhuD is distinct, both in sequence and structure, from canonical heme oxygenases (HOs) but homologous with IsdG-type proteins. Canonical HO is found mainly in eukaryotes, while IsdG-type proteins are predominantly found in prokaryotes including pathogens. While there are several published structures of MhuD and other IsdG-type proteins in complex with heme substrate, no structures have been reported of IsdG-type proteins in complex with product, unlike HOs. We recently showed that the Mtb variant MhuD-R26S produces biliverdin IXa (aBV) rather than the wild-type (WT) mycobilin isomers as product. Given that mycobilin and other IsdG-type protein products like staphylobilin are difficult to isolate in quantities sufficient for structure determination, here we use the MhuD-R26S variant and its product aBV as a proxy to study the IsdG-type protein/product complex. First we show that aBV has nanomolar affinity for MhuD and the R26S variant. Second we determined the MhuD-R26S-aBV complex structure to 2.5 Å, which reveals two notable features (1) two aBV molecules bound per active site and (2) a new a-helix (a3) as compared with the MhuD-heme structure. Finally, by molecular dynamics simulations we show that a3 is stable with the proximal aBV alone. MhuD's high affinity for its product and structural and electrostatic changes that accompany substrate turnover suggest that there is an unidentified protein that is responsible for product extraction from MhuD and other IsdG-type proteins.
Introduction
Heme degradation is important for a variety of biological functions, including iron reutilization, cell signaling, and antioxidant defense (Brouard et al., 2000; Dore et al., 1999; Ferris et al., 1999) . The well-studied canonical heme oxygenase (HO), human HO (hHO-1), catalyzes the oxidative cleavage of heme to release biliverdin XIa (aBV, Figure 1A) , ferrous iron, and carbon monoxide (CO) (Matsui et al., 2010; Tenhunen et al., 1969; Yoshida et al., 1980) . HO homologs have also been found in many eukaryotes and some prokaryotes including the pathogens, Corynebacterium diphtheriae, Pseudomonas aeruginosa and Neisseria meningitidis, and predominately produce the same heme degradation products (Ratliff et al., 2001; Schmitt, 1997; Wilks, 2002; Wilks and Schmitt, 1998; Zhu et al., 2000) . In eukaryotes, the HO reaction is coupled with the conversion of biliverdin (BV) to bilirubin by biliverdin reductase (BVR) (Noguchi et al., 1979) . After conjugation of bilirubin with glucuronic acid, bilirubin is excreted (Mantle, 2002) . The fate of HO-produced BV in prokaryotes has not been well studied thus far. Although in P. aeruginosa, it has been shown that extracellular acquired heme is degraded by a HO homolog, HemO, whereby the BV by-product is then excreted, but not further reduced, by an unknown mechanism (Barker et al., 2012) .
There is a heme-degrading protein family distinct, both in sequence and structure, from canonical HOs mainly found in bacteria, and termed the iron surface determinant G (IsdG)-type family (Chim et al., 2010; Skaar et al., 2004; Wu et al., 2005) . Staphylococcus aureus IsdG and IsdI were the first members characterized (Skaar et al., 2004; Wu et al., 2005) , and instead of degrading heme to BV, iron and CO, these enzymes cleave and oxidize heme at the β-and δ-meso carbon sites to produce staphylobilin isomers ( Figure   1A) , free iron and formaldehyde Reniere et al., 2010) . Other IsdGtype enzymes have been identified including MhuD from Mycobacterium tuberculosis (Mtb) and LFO1 from eukaryotic Chlamydomonas reinhardtii, and both degrade heme into unique products (Chim et al., 2010; Lojek et al., 2017) . While LFO1 degrades heme into a yet-to-be-determined product(s) (Lojek et al., 2017) , MhuD has been shown to degrade heme into iron and mycobilin isomers (Figure 1A) . Like staphylobilins, the mycobilin isomers are also oxidized at the β-or δ-meso carbons; however cleavage occurs at the α-meso carbon with no observed loss of a C1-product . It was proposed that there is no C1-product as hHO-1 produced CO triggers the transition of Mtb from its active to latent state . The fate of the IsdG-type protein heme degradation tetrapyrrole products, like staphylobilin and mycobilin, is unknown; however they may have antioxidant properties similar to BV (Vanella et al., 2016) .
The structures of HO and IsdG-type proteins are quite distinct. HOs are comprised of a monomeric α-helical domain (Schuller et al., 1999) , while IsdG-type proteins consist of a dimeric b-barrel decorated with two α-helices from each monomer (Wu et al., 2005) .
Unsurprisingly, the two distinct classes of heme-degrading enzymes degrade heme by different mechanisms (Matsui et al., 2016) . Although heme is coordinated by a proximal His residue in both HO and IsdG-type enzymes, the heme molecule in HOs is near-planar, while for IsdG-type proteins, the heme is ruffled (Schuller et al., 1999; Wu et al., 2005) .
Furthermore, HO has a distal pocket with a network of ordered water molecules that facilitates the three consecutive monooxygenase steps required for heme degradation (Matsui et al., 2010) . In contrast, the distal heme pocket is quite hydrophobic for IsdGtype proteins, with only one or two ordered waters observed in the proximal pocket (Graves et al., 2014; Wu et al., 2005) . In MhuD, it has been proposed that the hydrophobic pocket together with the ruffled heme contributes to the sequential monooxygenase and dioxygenase steps necessary for MhuD to degrade heme (Matsui et al., 2016) .
The structures of both human and C. diphtheriae HO complexed with aBV illustrate that the HO heme degradation reaction is coupled with a conformational change from a 'closed 'to 'open' state (Lad et al., 2004; Unno et al., 2013) . In both the eukaryotic and prokaryotic HO structures, the open-product bound state results from relaxation of the distal and proximal helices, and a rotation of the catalytic His side-chain out of the active site pocket as it is no longer coordinated to heme-iron (Lad et al., 2004; Unno et al., 2013) . This structural shift suggests that a degree of protein flexibility is necessary amongst the HO homologs to facilitate catalysis. Structures of apo and monoheme bound forms of IsdG-type proteins reveal an analogous conformational change in the catalytic His residue as it is absent or disordered in the apo structures; however the ordering of the elongated L2 loop region upon heme binding is a much more drastic conformational shift as compared with HOs (apo-MhuD; Protein Data Bank (PDB) ID: 5UQ4) (Graves et al., 2014; Lee et al., 2008; Wu et al., 2005) . Compared with other studied IsdG-type proteins, the MhuD active site is exceptionally flexible and can accommodate two molecules of heme, resulting in protein inactivation (Chim et al., 2010; Graves et al., 2014) . The biological significance of this conformational plasticity and its role in product turnover is not well understood as there is no structure of an IsdG-type enzyme in its product-bound form.
The structure of an IsdG-type protein in complex with its heme degradation product would further our understanding of the mechanism of action of this protein family. Staphylobilin and mycobilin products of IsdG-type proteins are difficult to purify Reniere et al., 2010) , which has presumably hindered the structural analysis of the product-bound form. Recently, we demonstrated that a MhuD variant, MhuD-Arg26Ser ( Figure 1B) , upon heme degradation produces aBV, formaldehyde and iron . In this current study, we determine the affinity of MhuD and the MhuD-R26S variant to both heme and aBV, and show they both bind heme and aBV in the nanomolar range. This high affinity to aBV has allowed us to utilize the MhuD-R26S variant as a proxy to study the IsdG-type proteins in complex with product. Upon solving the crystal structure of the MhuD-R26S-aBV, we observed the formation of a novel secondary structural element as compared to the heme-bound MhuD structure, and its implications will be discussed further.
Methods

Fluorescence-detection of ligand binding
Fluorescence-detected titrations of heme and αBV were carried out using a protocol previously described (Thakuri et al., 2018) . Stock solutions of MhuD (80 nM), heme (8 µM), and αBV (8 µM) were prepared in 50 mM Tris/HCl pH 7.4, 150 mM NaCl. Heme or αBV was titrated and gently mixed in 16 nM or 32 nM increments into MhuD-WT or MhuD-R26S. Following a 1-min incubation, fluorescence emission spectra were acquired between 320 to 500 nm on a Hitachi F-4500 Fluorescence Spectrophotometer through excitation at 285 nm with the following parameters: 1/3 nm step size, scan speed of 240 nm/min, PMT voltage of 700 V, and slit widths at 10 nm (MhuD WT) and 20 nm (MhuD-R26S).
Fluorescence emission spectral analysis
Results from the above fluorescence-based assay were fitted to Eqn. 1 derived from Conger et el (Conger et al., 2017; Thakuri et al., 2018) , to determine the equilibrium dissociation-constant (Kd) of heme or αBV with MhuD and its mutants. 
Expression and purification of Mtb MhuD and the R26S variant
Wild-type (WT) MhuD and the R26S variant were purified as previously reported Chim et al., 2010) . In brief, E. coli B21-Gold (DE3) cells transformed with pET22b-MhuD plasmid were grown in LB medium containing 50 μg/mL ampicillin at 37°C. Overexpression was induced at OD600 of ~ 0.6 using 1 mM IPTG. The cells were harvested 4 hours post induction and resuspended in lysis buffer (50 mM Tris/HCl pH 7.4, 350 mM NaCl and 10 mM imidazole). Cells were lysed via sonication and the resulting lysate was centrifuged at 14,000 rpm. The cell supernatant was loaded onto a Ni 2+charged HiTrap chelating column (5 mL) and washed with lysis buffer. Bound protein was eluted from the column with increasing concentrations of imidazole. Next, MhuD, which elutes at 50 and 100 mM imidazole, was concentrated (Amicon, 5 kDa molecular mass cutoff) and was further purified on a S75 gel filtration column in 20 mM Tris/HCl pH 8, and 10 mM NaCl.
Crystallization of MhuD-R26S-αBV complex
To prepare an αBV solution, approximately 2 mg of αBV hydrochloride (SigmaAldrich) was dissolved in 500 μL 0.1 M NaOH followed by 500 μL 1 M Tris/HCl pH 7.4 before dilution into 50 mM Tris/HCl pH 7.4, 150 mM NaCl. A ferric chloride solution was prepared by dissolving 27.3 mg of ferric chloride hexahydrate (SigmaAldrich) in 10 mL water. A 1.3 fold excess of a 1:1 molar ratio solution of αBV and ferric chloride was gradually added to 100 μM apo-MhuD R26S and incubated overnight at 4°C before being concentrated to 10 mg/mL (Lowry assay (Lowry et al., 1951) ). Light blue crystals appeared in 0.1 M HEPES pH 6.5, 4.6 M NaCl, 30 mM glycyl-glycyl-glycine after 2 days. The crystals were flash frozen in 100% NVH oil and a data set to 2.5 Å was collected at 70K. The collected data was indexed, integrated, and reduced using iMOSFLM (Battye et al., 2011) . Initial phase determination was carried out using Phaser in the PHENIX suite (Adams et al., 2010) using WT MhuD-heme-CN structure as a search model (PDB ID 4NL5) (Graves et al., 2014) . αBV molecules were positioned into appropriate positive electron density in the vicinity of the active site, and the structure was refined using phenix.refine (Adams et al., 2010) . For each promoter, the electron density of the loop region between Ala24 to Asn32 is poorly defined and residues His25-Val30 were modeled as alanines. The only
Ramanchandran outliers are Val30 modeled as Ala in both Chain A and B, which are in this poorly defined region of electron density.
Molecular dynamics (MD) simulations
The input files for MhuD 4NL5 -heme and MhuD 4NL5 -aBV simulations were prepared from the structure of dimeric MhuD-heme-CN and MhuD 4NL5 -heme did not include the cyano group (PDB ID: 4NL5). For the MhuD-aBV complex, input files were prepared from the MhuD-R26S-aBV structure, wherein the R26S mutation was reversed and just one aBV Hydrogen atoms were added to the system using pdb4amber from AmberTools15 with default protonation states (Case et al., 2015) . For simulations of MhuD 4NL5 -aBV, the coordinates of heme atoms served as a scaffold upon which each aBV was manually docked. aBV was parameterized using antechamber from AmberTools15 (Case et al., 2015) with GAFF version 1.7 and AM1-BCC charges. The ligated His75-Fe-heme ligand was parameterized according to previously published Density Functional Theory calculations (Harris et al., 2001) . Missing atoms for each structure were added using tleap in AmberTools15 (Case et al., 2015) , and parameterized using ff99SBildn (Lindorff-Larsen et al., 2010). Each system was explicitly solvated in tleap with a 10 Å rectangular box of TIP3P water, extending from the surface of the protein to the box edge, and sodium ions were added to neutralize the charge of the system.
Minimization proceeded using sander from Amber14 (Case et al., 2015) with steepest descents running for 20,000 timesteps of 2 fs each, followed by heating from 100 K to 300 K with constant volume for 25,000 timesteps of 2 fs. Equilibration continued using sander for 500,000 timesteps of 2 fs under constant pressure with positional restraints initially applied on all non-water atoms at 50 kcal/mol/Å 2 and progressively lifted in increments of 5 kcal/mol/Å 2 over ten 50,000 step segments. The resulting topology and coordinate files for each system were used as inputs for MD simulations. Production simulations were executed in OpenMM 7.1.0 (Eastman et al., 2017) using a Langevin integrator with a 2 fs timestep and a friction coefficient of 10/ps. For each of the three systems, five independent simulations of 100 ns each were initiated with randomized velocities. Among the five simulations, one simulation was restarted for each system for an additional 500 ns, bringing the total simulation time to 1 µs/system.
MD analysis
Distances and secondary structure assignments were computed using MDTraj (McGibbon et al., 2015) . For analysis, each monomer of MhuD was treated independently with the assumption that long-range interactions between each subunit are negligible for the time scales simulated here. To analyze the orientation of His75 during simulations, two orientations were defined: 1) Active Site -side chain pointing into binding pocket, towards the center of the tetrapyrrole, and 2) Solvent Exposed -side chain flipped away from the binding pocket, as in the MhuD-αBV structure (see Figure 4Bi ). To assign these positions, we computed the distance between the e nitrogen atom (furthest from the backbone) on His75 and the nitrogen atom located between the a and β carbons on either aBV or heme. If the distance was less than 6 Å, the His75 residue was classified as being oriented in the Active Site position; otherwise the position was classified as Solvent Exposed.
For the Arg79 positional analysis, we identified four positions; 1) Active site -Arg79 directed into the binding pocket interacting with the ligand, 2) Helix 1 -Arg79 side-chain interacting with residues on a-helix-1 (i.e residues 16-25) of MhuD, 3) Helix 2 -Arg79 side-chain interacting with residues on a-helix-2 (residues 60-75), and 4) Solvent 
Results
Affinity of substrate and product to MhuD
Previously, the affinity (Kd) of WT MhuD for heme was measured to be ~6 nM (Thakuri et al., 2018) ; empirically it has been also been observed that MhuD also has a high affinity for its product, as isolation of MhuD mycobilin products requires an iron-chelator followed by protein denaturation Nambu et al., 2013) . Recently, we demonstrated that the MhuD-R26S variant degrades heme to produce aBV as its predominate tetrapyrrole product rather than the WT MhuD mycobilin isomers Nambu et al., 2013) . As it is difficult to isolate large quantities of mycobilin, we use the MhuD-R26S variant and its aBV product as a model system to study IsdG-type proteins in complex with product. First, we determined the affinities of heme and aBV to both WT MhuD and the R26S variant. The heme affinity was measured using a previously described fluorescence-based assay (Figure 2) (Thakuri et al., 2018) .
The Kd of heme for MhuD-WT and MhuD-R26S are similar, both about 6 nM ( Table 1) ,
whereas the Kd values of aBV for MhuD-WT and MhuD-R26S are ~36 nM and ~92 nM, respectively ( Table 1 ). The fact that WT MhuD binds aBV with a higher affinity than the R26S variant (even though the product of WT MhuD is mycobilin rather than aBV) implies that the Arg26 residue may form contacts with the tetrapyrrole product.
The structure of the MhuD-R26S-aBV complex
To investigate the structural impacts on MhuD arising from heme degradation into product, we turned our attention to structure determination of the MhuD-R26S variant in complex with αBV. The MhuD-R26S-αBV complex crystallized in the presence of ferric chloride, and light blue crystals appeared in 0.1 HEPES pH 6.5, 4.6 M NaCl and 30 mM glycyl-glycyl-glycine after 2 days. The structure of the MhuD-R26S-αBV complex was solved to 2.5 Å resolution with a final R/Rfree of 23.2/28.5 ( Table 2) . The asymmetric unit contains two MhuD-R26S promoters bridged between their active sites by five partially πstacked αBV molecules ( Figure 3A) . The MhuD-R26S monomers each complexed with two αBV molecules superimpose with a root-mean-square deviation (RMSD) of 0.2 Å.
The biologically relevant MhuD-R26S homodimer is observed in the crystallographic 2fold symmetry (Figure 3B) , similar to the apo-and heme-bound MhuD structures (apo-MhuD; PDB code: 5UQ4) (Chim et al., 2010; Graves et al., 2014) .
The MhuD-R26S-αBV structure is similar to that of the MhuD-heme-CN and MhuDdiheme structures (Chim et al., 2010; Graves et al., 2014) , where each subunit forms a ferredoxin-like fold. Two monomers form a dimeric antiparallel β-barrel where each monomer has three α-helices together with two flexible loop regions; the first loop connects α-helix-1 to β-strand-2 and the second connects α-helix-3 to β-strand-4 ( Figure   3B ). It should be noted that the topology of the MhuD-R26S-αBV complex differs from the structures of apo-MhuD and heme-bound WT-MhuD (Graves et al., 2014) . Within the MhuD-R26S-αBV structure, there is an additional short α-helix-3 formed by residues Ala76-Asn81, which was not observed in the monoheme, diheme and apo-MhuD structures (Chim et al., 2010; Graves et al., 2014) , and thus the latter structures have a slightly longer extended L2 loop region. There are also other subtle conformational changes that will be discussed later. Along with the proximal and distal αBV molecules, there is a third 'bridging' αBV, which connects the two symmetrical promoters each bound to two αBV molecules (Figure 3A) . (Figure 4Bii) ; notably His78 is still solvent-exposed and weakly stabilized by a cationπ interaction between its imidazole side-chain and Arg22 (3.7 Å).
Another minor structural difference between substrate and product bound MhuD complexes is the unraveling of the C-terminal α-helix-1 in MhuD-R26S-αBV compared to MhuD-heme-CN. Arg26 is situated in this location and participates in a water-mediated H-bond with one of the heme propionates in the MhuD-heme-CN structure (Graves et al., 2014) (Figures 1B & 4A) . Within the MhuD-R26S-αBV structure, this region is no longer helical. Thus, this observed unraveling of α-helix-1 may be the result of the Arg26Ser mutation, however, this conformational change ensures that the backbone carbonyl group of the subsequent residue, Ala27, is in H-bonding distance of the imidazole nitrogen of His75, to stabilize the flipped out His75 in the MhuD-R26S-αBV structure .
The conformational change from going from substrate to product bound also alters the active site pocket volume and the electrostatic potential of the molecular surface ( Figures   4C & 4D) . The active site volume increases dramatically from heme bound to that of αBV, from 188 to 354 Å 3 , calculated utilizing CASTp (Tian et al., 2018) . In conjunction with the increased active site volume, the molecular surface region surrounding the active site and the L2 loop region undergoes an electrostatic potential change. The MhuD molecular surface surrounding one side of the exposed active site is positively and negatively charged in the presence of heme (Figure 4C) , whereas in the presence of αBV it becomes more hydrophobic and negatively charged with a positively charged bridge capping the active site ( Figure 4D) . Furthermore, when rotated 90° about the y-axis, there is an altered molecular surface electrostatics from positively charged and hydrophobic to predominately negatively charged in the presence of heme and αBV, respectively (Figures 4C & 4D , right panels).
Proximal αBV is representative of the MhuD physiological product
Within the MhuD-R26S-αBV structure, the orientation of the proximal αBV is representative of the MhuD physiological product, mycobilin. The proximal αBV adopts a similar orientation as heme in the MhuD-heme-CN structure (Figures 4A-B ) (Graves et al., 2014) , however αBV is rotated approximately 20° about the plane compared to heme-CN and the tetrapyrrole ring structure of αBV is considerably more twisted compared to heme. Additionally, the overall conformation of MhuD proximal αBV is similar to the αBV product of C. diphtheriae HmuO (PDB 4GPC) (Unno et al., 2013) , representative of the all-Z-all-syn type BV conformation. However, in another structure of hHO-1 in complex with αBV (PDB 1S8C) (Lad et al., 2004) , the αBV occupies an internal cavity adjacent to the active site and exhibits a more linear extended conformation. This was proposed to be the route of αBV dissociation from hHO-1 in the absence of BVR (Lad et al., 2004) . As αBV is bound tightly to MhuD, we did not anticipate that we would observe a partially dissociated product conformation or location, as seen in the hHO-1 structure. Thus these observations suggest that the proximal αBV within MhuD-R26S-αBV structure is the physiological orientation of the MhuD tetrapyrrole product, mycobilin, within the active site.
MD Simulations
MD simulations were performed to gain further insight into the protein conformational changes associated with heme and aBV binding. In particular, we wanted to evaluate the in silico stability of the MhuD α-helix-3 (Ala76-Asn81) in the presence of proximal αBV alone. MD simulations were set up using the biological dimer of the MhuD-R26S-αBV structure with the R26S mutation modeled as WT Arg26 and only the proximal αBVs retained. Over the 1 µs of combined simulation time, including a continuous 600 ns simulation, the α-helix-3 persisted for over 70% of the run, suggesting that the α-helix-3 is stable when there is just one αBV molecule present per active site. Interestingly, we also observe some helix formation within the L1 loop region, an otherwise highly flexible region of the protein (Figure 5A) .
To test if the α-helix-3 forms during turnover from heme to product, two more sets of simulations were carried out. The first contained the MhuD-heme-CN structure without the cyano group (MhuD 4NL5 -heme) while the second was comprised of the MhuD 4NL5 protein structure with αBV docked in place of heme to give MhuD 4NL5 -αBV. As with MhuD-αBV, these simulations each ran for a total of 1 µs. Although the two αBV MD systems (MhuD-αBV and MhuD 4NL5 -αBV) are identical in composition, they have distinct initial positions and velocities; MhuD-αBV simulations start from the coordinates of the αBVbound crystal structure while MhuD 4NL5 -αBV simulations start from those of the hemebound structure. Given sufficient simulation time, the dynamics of these two systems should eventually converge. While we did not reach convergence, it is compelling that we see some de novo formation of the α-helix-3 in our simulation of MhuD 4NL5 -αBV ( Figure   5B ), suggesting that it is a relevant structural motif that forms in the presence of αBV. We suspect that the α-helix-3 may be further stabilized by contact of MhuD with other interacting proteins. This α-helix-3 is also transiently observed in the MhuD 4NL5 -heme simulation (Figure 5C) ; however its occurrence is less frequent compared to MhuD 4NL5 -αBV.
We also sought to evaluate whether the 90° rotation of the catalytic His75 side chain away from the active site, as observed in the MhuD-αBV structure (Figures 4Bi & 6) , is facilitated by substrate turnover to αBV. In the MhuD-αBV simulations, His75 residue remains in the "flipped out" or solvent exposed orientation (Figure 6B ) while in the MhuD 4NL5 -heme simulations, it is ligated to the heme-iron atom and thus remains tethered to the active site. For MhuD 4NL5 -αBV, the His75 alternates between the two orientations ( Figure 6C) , as shown in Figures 6A & 6B . The solvent exposed position may be further stabilized in the MhuD 4NL5 -αBV simulations after extended simulation time and upon full formation of the α-helix-3, as observed in the MhuD-αBV structure, where the Arg79 sidechain forms a hydrogen bond with the backbone carbonyl of Ile72 (Figure 4Bii) .
Because the Arg79 side-chain is unresolved in the MhuD 4NL5 -heme structure but stabilized in the MhuD-αBV structure, we were also interested in exploring its dynamics in the presence of heme versus αBV. Upon inspection of the MhuD 4NL5 -heme simulations, four classifications of Arg79 positions were identified: helix 1 and helix 2 (interacting with residues on α-helix-1 or on α-helix-2), active site (interacting with heme or αBV) and solvent exposed (Figures 7A-D) . In the MhuD 4NL5 -heme simulations, the varied distribution of the Arg79 positions mirrors its disorder in the crystal structure (Figure 7E) .
Unexpectedly, we found at times that the Arg79 forms H-bonds with the propionate groups of the heme; in fact, in the extended 600ns simulation of MhuD 4NL5 -heme, the Arg79 residue for one MhuD subunit flipped into the active site and remained coordinated to the heme ligand for over 90% of the simulation (data not shown). In simulations with αBV, Arg79 interacts with residues on helix 2 or becomes solvent exposed. Consistent with the MhuD-αBV structure, the predominant state in the MhuD-αBV simulations shows it interacting with helix 2 (Figure 7F) . In our MhuD 4NL5 -αBV simulation, the favored state is solvent exposed (Figure 7G) , but we suspect the interaction of Arg79 with helix 2 may be further stabilized upon full formation of α-helix-3. Given that we only observe Arg79
interacting with the ligand propionate groups in simulations where His75 is oriented into the active site, we hypothesize that Arg79 plays a critical role in promoting catalysis (when heme is present) and facilitating product egress (via formation of α-helix-3).
Together these results suggest that in the MhuD-R26S-αBV structure we are (1) observing the proximal αBV in a location equivalent to the turnover product, (2) that the additional α-helix-3 present in the MhuD-product complex is not a crystallographic artifact and (3) the 90° rotation of His75 out of the active site is consistent with substrate turnover.
Discussion
Within the PDB there is only one other protein structure with a strikingly similar αBV stacking conformation in its active site, a BVR from cyanobacteria (Takao et al., 2017) .
As with the MhuD-R26S-αBV structure, the BVR-αBV structure has offset nearly parallel tetrapyrrole planes stacked at van der Waals distance and although the proximal and distal αBV molecules in MhuD have no inter-molecular H-bonds, the BVR αBV molecules form an intermolecular H-bond between the lactam oxygen and pyrrole nitrogen, as observed between the distal and 'bridging' αBV molecules in the MhuD-R26S-αBV asymmetric unit (Figure 3A) .
Tetrapyrrole stacking is sometimes important for enzyme activity, however it has also been observed that heme-heme stacking can be the product of crystallization. Heme stacking has previously been shown to be involved in protein electron transfer reactions, for example, the NapB, a cytochrome subunit of nitrate reductase requires two stacked heme molecules for electron transfer (Brige et al., 2002) . More recently it was demonstrated that the cyanobacterial BVR required two stacked BVs to reduce BV to bilirubin (Takao et al., 2017) by an unprecedented mechanism. In contrast, MhuD can also accommodate two stacked heme molecules per active site, although this renders the enzyme inactive (Chim et al., 2010) . Tetrapyrrole stacking at the crystallographic interface is not unprecedented, as observed in the structures of MhuD-diheme (Chim et al., 2010) , and the ChaN-heme (Chan et al., 2006) , an iron-regulated lipoprotein implicated in heme acquisition in Campylobacter jejuni. As MhuD is known to be active only in its monoheme form (Chim et al., 2010) , and thus only produces one molecule of product per active site, we hypothesize that the proximal αBV is in the correct orientation of the MhuD tetrapyrrole product; consequently, the three additional stacked αBV molecules adjoining the two active sites of adjacent MhuD promoters are likely a product of crystallization. also bind another molecule of heme resulting in its diheme inactive form, whereby the kinked α-helix-2 is now extended and His75 binds to heme-iron of the solvent exposed heme molecule, nearly tripling the volume of the active site from ~190 Å 3 to ~530 Å 3 compared to the monoheme structure (Tian et al., 2018) . Alternatively, when MhuDmonoheme turns over in the presence of an electron source, it forms the MhuD-product structure, which leads to the further unraveling of the C-terminal of α-helix-1 and the kinked α-helix-2 along with the formation of α-helix-3. With the transformation of substrate to product, the active site of MhuD doubles in volume, from ~190 Å 3 to ~360 Å 3 (Tian et al., 2018) . The four different conformational states of MhuD highlight this protein's inherent flexibility (Figure 8B) , which may be harnessed to produce MhuD inhibitors.
Little is known about the fate of IsdG-like protein products; but removal of their tetrapyrrole products requires protein denaturation Reniere et al., 2010) . Indeed, our previous and current work suggest that both MhuD substrate and product bind in the low nanomolar range and therefore the displacement of product by substrate would only occur at high heme concentrations in vivo (Thakuri et al., 2018) . We propose three possible mechanisms of MhuD product release; (1) a dramatic conformational change would reduce product affinity and result in dissociation, (2) IsdG-type proteins are 'suicide'
proteins that after one turnover require degradation or (3) an accessory protein is required for the removal of product from the MhuD active site. Although MhuD is an inherently flexible protein, as described above, its high affinity for tetrapyrroles decreases the likelihood that a conformational change alone would promote product release. Because it has been shown that S. aureus IsdG is degraded in vivo in its apo form, yet stabilized in the presence of heme (Reniere et al., 2011) , it seems unlikely that IsdG-type enzymes are also degraded when bound to product. As the MhuD-R26S-αBV complex structure has a newly formed structural element and an associated shift in molecular surface electrostatics in comparison to MhuD-monoheme complex, these conformational changes may promote protein-protein interactions to aid in product removal.
Protein-protein interaction-induced product removal is reminiscent of human HO-1 BV removal. Human BVR interacts with hHO-1, albeit via a weak interaction, to remove the product BV and further reduce it to bilirubin (Maines and Trakshel, 1993) . In contrast, the well-studied bacterial HO from P. aeruginosa excretes BV without further reduction (Barker et al., 2012) . We hypothesize that a yet-to-be-identified Mtb protein removes product from MhuD and potentially aids in its eventual excretion, as observed in the human HO system. Surprisingly, Mtb has four close homologs of BVR even though Mtb does not have a conventional BV-producing HO enzyme (Chim et al., 2010) . One of these homologs, Rv2074, has BV reduction activity although its electron donating cofactor is the flavin cofactor F420 (Ahmed et al., 2016) , a deazaflavin cofactor that is a low potential hydride transfer agent (Bashiri et al., 2019) , rather than flavin mononucleotide (FMN) as observed for eukaryotic BVRs (Sugishima et al., 2018) . In contrast, Rv1155
does not readily reduce BV (Ahmed et al., 2015) . Consequently, it was proposed that one of the BV inactive Mtb BVRs catabolizes mycobilins. Rv2607 and Rv2991 have not been tested for BVR activity and could also act in MhuD product breakdown (Ahmed et al., 2015) . Mtb has both heme and siderophore-mediated iron acquisition systems , however Mycobacterium leprea only has a heme uptake and catabolism pathway. The M. leprea proteome only has the Mtb BVR homologs, Rv1155 and Rv2607, suggesting one of these proteins is perhaps involved in MhuD product removal.
Finally, the MhuD-product complex has an additional α-helix-3 and an accompanying change in electrostatic surface potential, compared to the MhuD-substrate complex, which may be essential for mediating protein-protein interactions to promote product removal. Notably, S. aureus IsdG and IsdI have a similar 75 HisXXXArg 79 motif encompassing the α-helix-3 (Figure 9 ), suggesting that both S. aureus IsdG and IsdI also form the new secondary structure element upon product formation; this may be a common structural feature among all IsdG-type proteins in complex with product. Arg79 predominantly interacts with helix 2 residues and may be stabilized by its participation in a-helix-3. For G. MhuD 4NL5 -aBV, where heme has been removed from the MhuD-monoheme structure and aBV is docked in its place, the Arg79 remains mostly solvent exposed. 
Figure Legends
